Novartis states that U.S. courts uphold Gillenia patents

The logo of the Swiss pharmaceutical company Novartis can be seen on October 23, 2017 at its factory in the town of Stein in northern Switzerland. (Arnd Wiegmann / Reuters)

ZURICH-Novartis AG on Tuesday upheld the validity of a drug planning patent for the multiple sclerosis drug Gilenya by a U.S. Court of Appeals and issued a permanent injunction against Chinese generic drug company HEC Pharma until the patent expires in 2027. He said he could continue.

“This decision will enable us to confirm the validity of the patent and maintain its injunction,” a Swiss pharmaceutical company said in a statement, saying that the generic version of Gillenia in the U.S. market for at least the next two years. He added that he expected that there would be no.

Monday’s Federal Circuit’s Division Committee rejected HEC’s allegations that the patent lacked proper written explanation and blocked the company’s bid to sell a generic version of Gilenia before the patent expired. did.

Silke Coltrowitz